Disappointing top-line results from the Phase III study with avatrombopag, an oral thrombopoietin receptor agonist (TPO), in cancer patients with solid tumors and cytostatics-induced thrombocytopenia (CIT), sent Swedish Orphan Biovitrum’s (STO: SOBI), also known as Sobi, shares plunging 19% to 180.70 Swedish kronor by late afternoon.
Although avatrombopag (trade name Doptelet), as expected, increased platelet counts relative to placebo, the study did not meet the combined primary endpoint for avoiding platelet transfusion, a dose reduction of 15% or more by chemotherapy, and a four-day delay in chemotherapy. or more. In the intent-to-treat population (complete analysis), 69.5% and 72.5%, respectively, of avatrombopag patients and placebo patients were considered to respond to the primary endpoint (p = 0.72). In the per-protocol population, 85.0% and 84.4%, respectively, of avatrombopag patients and placebo patients were considered to respond to the primary endpoint (p = 0.96).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze